BioCardia (BCDA) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioCardia (BCDA) has outperformed Scilex (SCLX) over the past year, losing 25.4% versus a loss of 73.0%. Over five years, BCDA leads with a -97.6% price change compared with -98.6% for SCLX. Scilex is the larger company by market cap ($20.8 million vs $16.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | SCLX |
|---|---|---|
| Share price | $1.06 | $2.96 |
| Market cap | $16.05M | $20.82M |
| 1-day change | -2.75% | -15.19% |
| YTD return | -15.20% | -61.03% |
| 1-year return | -25.35% | -72.96% |
| 5-year return | -97.59% | -98.65% |
| Forward P/E | — | 4.05 |
| EPS (TTM) | $-0.64 | $-49.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $16.81 |
| 52-week low | $0.75 | $2.62 |
| Distance from 52-week high | -41.11% | -82.39% |
| Analyst consensus | none | — |
| Avg. price target upside | +1362.26% | — |
| Average volume | 282.05K | 53.62K |
| Shares outstanding | 15.14M | 7.03M |
| Employees | 17 | 34 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed SCLX by 47.6 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
About Scilex
SCLX stock →Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Healthcare · Drug Manufacturers - General · 34 employees
BCDA vs SCLX FAQ
Which is bigger, BioCardia or Scilex?
Scilex (SCLX) is larger, with a market capitalization of $20.82M compared with $16.05M for BioCardia (BCDA).
Which stock has performed better over the past year, BCDA or SCLX?
BCDA returned -25.35% over the past 12 months, compared with -72.96% for SCLX (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and Scilex in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for BioCardia and Drug Manufacturers - General for Scilex.